KalVista Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US4834971032

Introduction

This page provides a comprehensive analysis of the known insider trading history of Audhya Paul K.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Audhya Paul K. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:KALV / KalVista Pharmaceuticals, Inc. CHIEF MEDICAL OFFICER 122,505
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Audhya Paul K.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases KALV / KalVista Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KALV / KalVista Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALV / KalVista Pharmaceuticals, Inc. Insider Trades
Insider Sales KALV / KalVista Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KALV / KalVista Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-08-25 KALV Audhya Paul K. 2,336 13.4200 2,336 13.4200 31,349 0 12.9900 -1,004 -3.20
2025-08-22 KALV Audhya Paul K. 2,942 13.2228 2,942 13.2228 38,901
2025-08-18 KALV Audhya Paul K. 2,939 13.1870 2,939 13.1870 38,757
2025-05-23 KALV Audhya Paul K. 2,146 11.3102 2,146 11.3102 24,272
2025-05-22 KALV Audhya Paul K. 2,689 11.8755 2,689 11.8755 31,933
2025-05-19 KALV Audhya Paul K. 2,776 11.8428 2,776 11.8428 32,876
2025-02-24 KALV Audhya Paul K. 2,394 10.0200 2,394 10.0200 23,988
2025-02-18 KALV Audhya Paul K. 3,125 9.8242 3,125 9.8242 30,701
2024-11-26 KALV Audhya Paul K. 2,187 9.8702 2,187 9.8702 21,586
2024-11-18 KALV Audhya Paul K. 8,077 9.2566 8,077 9.2566 74,766
2024-08-23 KALV Audhya Paul K. 2,135 12.4000 2,135 12.4000 26,474
2024-08-19 KALV Audhya Paul K. 7,973 12.0133 7,973 12.0133 95,782
2024-05-20 KALV Audhya Paul K. 13,175 11.7645 13,175 11.7645 154,997
2024-02-20 KALV Audhya Paul K. 14,295 14.1150 14,295 14.1150 201,774
2023-11-20 KALV Audhya Paul K. 7,985 8.2293 7,985 8.2293 65,711
2023-08-18 KALV Audhya Paul K. 8,020 10.7288 8,020 10.7288 86,045
2023-05-18 KALV Audhya Paul K. 2,780 10.1444 2,780 10.1444 28,201
2023-02-17 KALV Audhya Paul K. 3,412 7.6600 3,412 7.6600 26,136
2022-11-18 KALV Audhya Paul K. 722 5.4400 722 5.4400 3,928
2022-08-17 KALV Audhya Paul K. 725 14.9615 725 14.9615 10,847

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALV / KalVista Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Audhya Paul K. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-26 2025-08-25 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,336 122,505 -1.87 13.42 -31,349 1,644,017
2025-08-26 2025-08-22 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 5,000 124,841 4.17
2025-08-25 2025-08-22 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,942 119,841 -2.40 13.22 -38,901 1,584,634
2025-08-25 2025-08-21 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,250 122,783 5.36
2025-08-19 2025-08-18 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,939 116,533 -2.46 13.19 -38,757 1,536,721
2025-08-19 2025-08-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,446 119,472 5.70
2025-05-27 2025-05-23 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,146 113,026 -1.86 11.31 -24,272 1,278,347
2025-05-27 2025-05-22 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 5,000 115,172 4.54
2025-05-23 2025-05-22 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,689 110,172 -2.38 11.88 -31,933 1,308,348
2025-05-23 2025-05-21 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,250 112,861 5.86
2025-05-20 2025-05-19 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,776 106,611 -2.54 11.84 -32,876 1,262,573
2025-05-20 2025-05-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,447 109,387 6.26
2025-02-25 2025-02-24 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,394 102,940 -2.27 10.02 -23,988 1,031,459
2025-02-25 2025-02-22 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 5,000 105,334 4.98
2025-02-19 2025-02-18 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -3,125 100,334 -3.02 9.82 -30,701 985,701
2025-02-19 2025-02-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,447 103,459 6.65
2024-11-27 2024-11-26 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,187 97,012 -2.20 9.87 -21,586 957,528
2024-11-27 2024-11-22 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 5,000 99,199 5.31
2024-11-19 2024-11-18 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -8,077 94,199 -7.90 9.26 -74,766 871,962
2024-11-19 2024-11-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 18,531 102,276 22.13
2024-08-26 2024-08-23 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,135 83,745 -2.49 12.40 -26,474 1,038,438
2024-08-26 2024-08-22 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 5,000 85,880 6.18
2024-08-21 2024-08-19 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -7,973 80,880 -8.97 12.01 -95,782 971,636
2024-08-21 2024-08-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 18,528 88,853 26.35
2024-05-21 2024-05-20 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -13,175 70,325 -15.78 11.76 -154,997 827,338
2024-05-21 2024-05-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 30,614 83,500 57.89
2024-02-21 2024-02-20 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -14,295 52,886 -21.28 14.12 -201,774 746,486
2024-02-21 2024-02-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 30,613 67,181 83.72
2023-11-21 2023-11-20 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -7,985 36,568 -17.92 8.23 -65,711 300,929
2023-11-21 2023-11-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 18,530 44,553 71.21
2023-08-21 2023-08-18 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -8,020 26,023 -23.56 10.73 -86,045 279,196
2023-08-21 2023-08-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 18,529 34,043 119.43
2023-05-19 2023-05-18 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -2,780 13,014 -17.60 10.14 -28,201 132,019
2023-05-19 2023-05-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,447 15,794 68.97
2023-02-23 2023-02-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -3,412 9,347 -26.74 7.66 -26,136 71,598
2023-02-23 2023-02-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,446 6,313 -4,846.62
2022-11-21 2022-11-18 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -722 5,946 -10.83 5.44 -3,928 32,346
2022-11-21 2022-11-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 2,419 6,668 56.93
2022-08-19 2022-08-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
S - Sale -725 1,693 -29.98 14.96 -10,847 25,330
2022-08-19 2022-08-17 4 KALV KalVista Pharmaceuticals, Inc.
Common Stock
M - Exercise 2,418 2,418
2022-05-19 2022-05-17 4 KALV KalVista Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 38,700 38,700
2022-05-19 2022-05-17 4 KALV KalVista Pharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 25,800 25,800
2021-05-04 2021-05-01 4 KALV KalVista Pharmaceuticals, Inc.
Employee Stock Option (right to buy)
A - Award 100,000 100,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)